Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
about
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injuryStereoselective synthesis of novel pyrazole derivatives using tert-butansulfonamide as a chiral auxiliaryVinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanismImplementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases.The future of EPAC-targeted therapies: agonism versus antagonismIbudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalizationRemodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells.Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseRNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells.The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins.The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain.A new structure-based QSAR method affords both descriptive and predictive models for phosphodiesterase-4 inhibitors.Novel 5,6-dihydropyrazolo[3,4-E][1,4]diazepin-4 (1H)-one derivatives for the treatment of asthma and chronic obstructive pulmonary disease.The effects of selective and nonselective phosphodiesterase inhibitors on phagocytic cells in mice.3D-QSAR Study of Potent Inhibitors of Phosphodiesterase-4 Using a CoMFA Approach.Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.
P2860
Q21089854-7E46B442-C062-43E7-BCD0-2E46EB7316A3Q27677514-2D74C70D-6CED-4325-8819-6B5E9F28091EQ28281609-1FD8358B-4FF1-4E4A-9AAD-1399FD313AC9Q33285971-177FB014-0C73-4F45-9452-5777A4030A50Q34465923-9455C3BF-DB0A-4689-A719-F3EF1E5885B9Q34642112-CB4F4DB1-31CE-4300-A31E-214F94B101D9Q35005680-EB2BFD10-EA2F-4236-BB4D-34401A71321BQ35047129-565691BD-F8D2-4969-94A8-2D506EE3E83EQ35590068-04BFD483-2107-4757-A967-6748EA622AC5Q36334968-2CCD1D4B-1437-4646-8F63-C1DBE851FAFCQ36492905-15425E5F-7E4A-440B-8786-6DC6A11D600BQ37195453-357AC41E-3E41-4A44-A8AD-EF2E058A9F21Q37828179-BDB6D9CD-BC0F-4B4B-91E4-9D503A219B12Q40395764-8B55CB78-5E14-4E2E-8F4E-A3071819B07EQ40633113-80FE3B45-2B70-4E3B-9E49-3A2F17F24359Q41771736-936A072A-2E47-498B-917D-FE9CF69AFFDAQ42941297-2C1D352F-3EBA-4538-BB3D-7B5F19CB5B73Q42975073-60CEFF80-4232-4575-8702-FEA554A5496DQ43171690-B88CF81B-9201-45F4-8E69-17BC171DA845Q46029687-C999B1CC-5E53-4F92-BB16-37324276C0FBQ46142907-7369CF48-B00A-4BC0-977E-613BBB8B32AFQ47872223-3E9FCDDA-28BD-4C25-867C-FA78CC8E6839
P2860
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@ast
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@en
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@nl
type
label
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@ast
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@en
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@nl
prefLabel
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@ast
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@en
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@nl
P356
P1476
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
@en
P2093
Catherine Burnouf
Marie-Pierre Pruniaux
P304
P356
10.2174/1381612023394665
P577
2002-01-01T00:00:00Z